Plenary Session 3: Top Ranked Oral Abstracts
| Thursday, August 13, 2026 |
| 10:15 AM - 11:15 AM |
Speaker
Dr JISOO A Kwon
Lecturer
Kirby Institute
RETURN ON INVESTMENT 3: EVALUATING THE COST-EFFECTIVENESS OF NEEDLE AND SYRINGE PROGRAMS IN AUSTRALIA
10:15 AM - 10:27 AMBiography
Dr Amy Kwon is a mathematician at the Kirby Institute, UNSW. Her research involves the development of mathematical models to understand the epidemiology of HCV and predict the impact and cost-effectiveness of interventions. She is responsible for providing the key HCV estimates for Australia's Annual Surveillance Report.
Dr Roana Lobo
Associate Professor
Curtin University
Enhancing access to needle and syringe programs for Aboriginal peoples in Boorloo: The Healthy Blood Healthy Body project
10:30 AM - 10:42 AMBiography
Dr Roanna Lobo is a teaching and research academic with over 20 years’ experience in public health research and evaluation. She has expertise in participatory research with marginalised and vulnerable populations, including Indigenous peoples and migrants. Roanna’s research focuses on health equity, informing interventions, program design, policy and systems change.
Erica Parker
Public Health Physician
North Metropolitan Health Service
Hepatitis C elimination progress in Perth
10:45 AM - 10:57 AMBiography
Dr Erica Parker is a public health physician who oversees the blood-borne virus portfolio at Boorloo (Perth) Public Health Unit. She completed her medical training at UWA, followed by a PhD investigating acute HIV in Mozambique. Lately her team are focused on progressing hepatitis C elimination in Perth.
Dr Loren Brener
Professor
CSRH
Hepatitis B knowledge, stigma, and mistrust in healthcare among people of Filipino ethnicity in Australia: implications for culturally responsive prevention
11:00 AM - 11:15 AMBiography
Loren is a researcher at the Centre for Social Research in Health, UNSW. Her work focuses on stigma and discrimination, health equity, culturally inclusive and responsive care, and community-engaged responses to viral hepatitis and other BBVs/STIs among priority populations and culturally and linguistically diverse communities in Australia.